# US 2008/0305172 A1 · Ophthalmic depot formulations for periocular or suconjunctival administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305172 A1
- Document ID: US20080305172A1
- Status: Published application
- Kind: A1
- Application number: 12/194,617
- Filed: 2008-08-20
- Published: 2008-12-11
- Earliest claimed: 2001-09-14
- Inventors: Marklus Ahlheim; Michael Ausborn; David Bodmer; Christian Schoch
- Web page: https://patentgrep.com/patent/US20080305172A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 37/02: Immunomodulators
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration.

## Claims

### Claim 1

An ophthalmic depot formulation comprising an active agent for periocular or subconjunctival administration.

### Claim 2 (depends on 1)

A formulation according to claim 1 comprising of microparticles of essentially pure active agent.

### Claim 3 (depends on 1)

A formulation according to claim 1 wherein the active agent is embedded in a biocompatible pharmacologically acceptable polymer or a lipid encapsulating agent.

### Claim 4 (depends on 1)

A formulation according to claim 1 wherein the polymer is a poly-lactide-co-glycolide ester of a polyol.

### Claim 5 (depends on 1)

A formulation according to claim 1 wherein the polymer is a 40/60 to 60/40 polylactide-co-glycolide ester of a polyol.

### Claim 6 (depends on 1)

A formulation according to claim 1 comprising microparticles.

### Claim 7 (depends on 6)

A formulation according to claim 6 wherein the external surface of the microparticles is substantially free of active agent.

### Claim 8

A liquid formulation comprising a dissolved pharmaceutical acceptable polymer and a dissolved or dispersed active agent which formulation upon injection forms a depot at the injection site.

### Claim 9 (depends on 1)

A formulation according to claim 1 wherein the active agent is present in an amount of up to 300 mg per dose for single administration.

### Claim 10 (depends on 1)

A formulation according to claim 1 wherein the active agent is a staurosporine of formula (I), a phthalazine of formula (II) or an ophthalmically acceptable salt thereof.

### Claim 11

A method for treating an ocular disease which comprises:
i) providing a depot formulation comprising an active agent, and
ii) introducing said depot formulation periocularly or subconjunctivally.

### Claim 12 (depends on 11)

A method according to claim 11 wherein the active agent is embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent.

### Claim 13 (depends on 11)

A method according to claim 11 wherein the active agent diffuses from said depot formulation to the site of said ocular disease.

### Claim 14 (depends on 11)

A method according to claim 11 wherein the active agent is maintained at an effective dosage for said ocular disease at the site of said ocular disease for an extended period of time.

### Claim 15 (depends on 11)

A method according to claim 11 wherein the active agent is maintained at an effective dosage for up to 3 months.

### Claim 16

A microparticle comprising a staurosporine of formula (I), a phthalazine of formula (II) or an ophthalmically acceptable salt thereof embedded in a biocompatible pharmacologically acceptable polymer or a lipid encapsulating agent.
